(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2011 (28.04.2011)

PCT

(10) International Publication Number
WO 2011/050180 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61K 31/56* (2006.01)
A61K 31/535 (2006.01)

(21) International Application Number:
PCT/US2010/053579

(22) International Filing Date:
21 October 2010 (21.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/253,804 21 October 2009 (21.10.2009) US

(71) Applicant *(for all designated States except US)*: **IMMUNOGEN, INC.** [US/US]; 830 Winter Street, Waltham, Massachusetts 02451 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LAMBERT, John** [US/US]; 19 Chalk Street, Cambridge, Massachusetts 02139 (US). **O'LEARY, James, J.** [US/US]; 273 Watertown Street, Newton, Massachusetts 02458 (US). **SCHINDLER, Joanne Elizabeth Sarah** [US/US]; 31 Florence Street, Natick, Massachusetts 01760 (US). **WEITMAN, Steven** [US/US]; 11235 Hunters Path, Helotes, Texas 78023 (US). **QIN, Albert** [US/US]; 266 Highland Ave, Winchester, Massachusetts 01890 (US).

(74) Agents: **MACK, Susan J.** et al.; Sughrue Mion, PLLC, 2100 Pennsylvania Avenue, NW, Suite 800, Washington, District of Columbia 20037-3213 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/050180 A1

(54) **Title**: NOVEL DOSING REGIMEN AND METHOD OF TREATMENT

(57) **Abstract**: This invention relates to a method of treatment and dosing regimen for treating disease, such as cancer and mammalian tumors, wherein therapy with a cytotoxic drug is suitable, by the administration of an antibody-toxin conjugate, such as a maytansinoid toxin, by infusion at an initial infusion rate of 1 mg/min or lower on a schedule selected from the group consisting of: (1) an amount of at least about 90 mg/m^2 on day 1 and day 8, every three weeks; (2) at least an amount of about 30 mg/m^2 on day 1, day 2 and day 3, every three weeks; (3) at least an amount of about 45 mg/m^2 on day 1, day 8, and day 15, every 4 weeks; and (4) at least an amount of about 45 mg/m^2 on day 1, day 8 and day 15, every 3 weeks.